Jennifer Barrett, Associate Editor

According to the study, enzyme USP15 may regulate cancer cell response to poly-(ADP-ribose) polymerase inhibitors.

Novartis’ siponimod (Mayzent) is approved for adults with active secondary progressive multiple sclerosis, clinically isolated syndrome, and relapsing-remitting disease.

Preventive drugs are frequently continued in patients with cancer near end of life despite limited clinical benefit.

Although generic versions of prescription medications can be a cheaper alternative for patients, many perceive generics as less effective and less safe than their brand-name counterparts.

The findings could help promote interventions aimed at improving patient and provider confidence in generic drugs for managing chronic diseases.

A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.

When combined, treatment with metformin and heme suppressed tumor growth in mice.

The phase 3 RELAY trial met its primary endpoint in significantly improving progression-free survival in metastatic EGFR-mutated non-small cell lung cancer.

Specialty therapies for autoimmune diseases and cancer topped the list of biggest-selling drugs for 2018.

Study finds patients with negative beliefs about medications may be more likely to experience adverse effects when taking antiretroviral therapy.

Kaiser Family Foundation analysis examines Medicaid outpatient prescription drug utilization and spending before rebates.

Study provides insight into how prostate cancer transitions to an aggressive, treatment-resistant subtype following anti-androgen therapy.

A head-to-head trial evaluated quality of life improvements in patients with moderate-to-severe psoriasis treated with secukinumab (Cosentyx) or ustekinumab (Stelara).

Alvotech’s AVT02 is being developed as a biosimilar to the adalimumab (Humira, AbbVie) high-concentration product.

Phase 3 trial evaluated ustekinumab as a maintenance treatment in adult patients with moderate-to-severe ulcerative colitis.

The latest sBLA is based on a phase 3 study evaluating the daratumumab combination regimen for newly-diagnosed patients with multiple myeloma who are ineligible for transplantation.

Trastuzumab is indicated for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Trastuzumab is indicated for the treatment of HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

PARP inhibitors used alongside immunotherapy may help stimulate the immune response to cancer cells by attracting immune cells to the tumor.

The FDA recently published an updated draft guidance on the naming of biologics, biosimilars, and interchangeable biosimilars.

Dupilumab (Dupixent, Regeneron and Sanofi) would be the first FDA-approved biologic for the treatment of severe chronic rhinosinusitis with nasal polyps.

Dupilumab (Dupixent, Regeneron and Sanofi) would be the first FDA-approved biologic for the treatment of severe chronic rhinosinusitis with nasal polyps.

If approved, rilpivirine plus cabotegravir would be the first monthly dosing option for adult patients with HIV.

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

Ublituximab may provide a clinical benefit for patients with multiple sclerosis via lower doses and faster infusion times than current therapies.

There are currently no approved therapies for the prevention of episodic cluster headaches.

Researchers have made progress in understanding why Hispanic children are disproportionately affected by acute lymphoblastic leukemia.

The 2017 Health Care Cost and Utilization Report examined medical and prescription drug spending, utilization, and average prices using health care claims data from 2013 through 2017 for Americans under the age of 65 who were covered by employer-sponsored insurance.

The report analyzed cost and utilization trends across health care services among patients with employer-sponsored insurance.

Indivior’s once-monthly schizophrenia treatment risperidone (Perseris) extended-release injectable suspension has launched in the United States.